New hope for lung cancer patients: durvalumab after chemoradiotherapy shows promise

NCT ID NCT07309211

Recruiting now Disease control Sponsor: The First Affiliated Hospital with Nanjing Medical University Source: ClinicalTrials.gov ↗

First seen Jan 02, 2026 · Last updated May 20, 2026 · Updated 18 times

Summary

This study looks at whether the drug durvalumab can safely help control limited-stage small cell lung cancer after initial chemoradiotherapy. Researchers will review medical records of 25 patients who received durvalumab as a follow-up treatment. The main goal is to check for serious side effects within the first 6 months, and also to see how long the cancer stays under control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCLC, LIMITED STAGE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Cancer Hospital of Shandong First Medical University
RECRUITING

Jinan, China
Nanjing Chest Hospital
NOT_YET_RECRUITING

Nanjing, China
The First Affiliated Hospital with Nanjing Medical University
RECRUITING

Nanjing, China
The affiliated hospital of qingdao university
RECRUITING

Qingdao, China

Conditions

Explore the condition pages connected to this study.

SCLC, LIMITED STAGE